Loading
Life sciences · Review
World Journal of Urology · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose Bacillus Calmette–Guérin (BCG) therapy is a standard-of-care for non–muscle-invasive bladder cancer (NMIBC), and granulomatous prostatitis (GP) is a side effect often misdiagnosed as prostate cancer (PCa). We conducted a systematic review to clarify the clinical spectrum of BCG-induced GP. Methods MEDLINE, Embase, and Web of Science were searched in June 2026. We sought studies reporting GP associated with BCG therapy for NMIBC, including case reports and case series. Risk of bias was evaluated using ROBINS-I and JBI tools. Findings were synthesized narratively (CRD420261324758). Results Forty-seven studies were included, comprising 23 case reports, 19 case series, and 5 comparative studies. In case series, abnormal digital rectal examination findings were reported in 100/240 (42%) evaluable cases. PSA elevation (> 4 ng/mL) occurred in 104/194 (54%) patients but often declined spontaneously during follow-up. Suspicious MRI findings were common, with PI-RADS ≥ 4 lesions reported in 71/82 (87%) cases, whereas biopsy-confirmed PCa was detected only in 12/151 (7.9%) patients. However, Grade Group and definitions of clinically significant PCa (csPCa) were incompletely and inconsistently reported, precluding a reliable estimate of csPCa frequency. Limitations include the predominance of descriptive studies and potential selection bias. Conclusion BCG-induced GP frequently presents with transient PSA elevation and suspicious MRI findings that rarely indicate true PCa. In BCG-exposed patients with elevated PSA or PI-RADS ≥ 4 lesions, structured observation with careful follow-up should be considered before proceeding to immediate biopsy.